Good morning —
This past weekend, I was fooling in the data ..doing analystic things and as I am gearing up our Club Fund project, I wanted to get a handle on what’s happening in the major industries and what companies (known and unknown) are driving change.
I just watched the CEO of duostech, a safety, secuirty and data technology company hailing from Jacksonville, Florida talk about the 112% increase in quarterly revenue and their major business expansion goals.
I only found this company because of our data collecting system, and I am happy about that.
Duostech is pubically traded on Nasdaq. Duostech trades less than $9 a share (at the time of writing this) up from $5.80 in August. - but its more than just the price..we have to understand the financial reports behind the company. Assets, liabilites, debt, cost of debt, revenue, labor, disciplines, SWOT, and much more.
I am no genius behind any of this stuff - I just know that I want to know more..and that’s why I created Club Fund.
So, I did one further - I set up a quick logic system and allowed AI to go crazy in the data just to see what popped out. Then verified the data and sent it in to do the dirty work again. The logic is rudimentary, and of course, I linked it to what I want to achieve with Club Fund.
I’ll just give it to you straight!
🛑 P.S This is NOT investment advice. Everything here is purely educational.
Best Stock Investment Opportunities Based on Our Data and Why
(Based on ~4,740 of 7,656 processed records. There may be additional opportunities in the unprocessed data.)
1. IREN Limited (Nasdaq: IREN)
Why it stands out: IREN just inked a $9.7 billion multi‑year GPU cloud services contract with Microsoft Corporation, deploying NVIDIA GB300‑series GPUs at IREN’s Texas campus. Yahoo Finance Meanwhile, IREN has committed ~$5.8 billion of hardware via Dell Technologies to support this build‑out. Iris Energy
Potential: High — this is a transformational contract validating IREN’s pivot into AI infrastructure, giving clear visible scale and a large anchor customer.
Watchpoints: Execution risk (deliveries, deployment), high capex and financing needs.
2. Fractyl Health, Inc. (Nasdaq: GUTS)
Why it stands out: Fractyl reported randomized clinical data showing that its Revita® procedure maintained weight loss after GLP‑1 discontinuation — treated patients lost an additional 2.5% bodyweight vs the sham group which regained ~10%. Stock Titan It also has a strong cash runway into early 2027.
Potential: High — if this obesity/weight‑maintenance niche takes off (especially given interest in GLP‑1 alternatives/off‑ramps) this could be a growth story.
Watchpoints: As a clinical‑stage company it carries biotech/regulatory risk; market expectations may already price in some upside.
3. Greif, Inc. (NYSE: GEF / GEF.B)
Why it stands out: Greif has completed major divestitures (raising ~$2.3 billion), reduced leverage, and launched a ~$150 million share‑repurchase program for 2026. Fastbull Guidance for fiscal 2026: ~$630 million Adjusted EBITDA and ~$315 million Free Cash Flow. GlobeNewswire
Potential: Strong — improving balance sheet, disciplined capital returns, clear execution path to cash flow expansion.
Watchpoints: End‑markets (materials/containers) may soften; growth is more moderate than high‑flyer bets.
4. Cheniere Energy, Inc. (NYSE: LNG)
Why it stands out: Cheniere posted Q3 2025 results: revenue ~$4.4 billion (up ~18% y/y), net income ~$1.0 billion, and raised its full‑year distributable cash flow guidance from $4.4‑4.8 billion to $4.8‑5.2 billion. Cheniere Energy, Inc. It also repurchased ~$1 billion of stock in Q3, and increased its quarterly dividend by >10%. Nasdaq
Potential: Strong — leading LNG exporter with robust cash flows, capital returns and a structural energy tailwind (global LNG demand).
Watchpoints: Commodity/volume risk, regulatory & export risk, macro energy demand cycles.
5. Akero Therapeutics, Inc. (Nasdaq: AKRO)
Why it stands out: Akero is being acquired by Novo Nordisk A/S at $54/share in cash + up to $6/share contingent value rights, for a deal value up to ~$5.2 billion. Nasdaq The strategic buyer is investing in its pipeline for metabolic dysfunction‑associated steatohepatitis (MASH). Drug Discovery Trends
Potential: Immediate/defined upside — if you hold pre‑deal you have a clear buy‑out premium; if you buy now you’re buying into pending close and potential CVR value.
Watchpoints: Deal risk (closing risk, regulatory), and downside is limited if the acquisition falls through or the CVR isn’t realized.
Why these made the cut
Each of these companies shows visible corporate moves (contracts, acquisitions, repurchases, divestitures) — matching our data‑driven filter of “moves we can verify via filings/press” as well as our in-house logic.
They span sectors (biotech/obesity, energy, materials, infrastructure) — useful diversification within the signals universe.
They each include either a clear catalyst (deal closing, contract rollout, clinical data) or improving fundamentals (cash flow growth, capital returns) — aligning with our approach of where capital flows and where execution matters.
Key takeaways & disclaimers
These picks reflect opportunity, not guarantee. Execution risk is high, especially in biotech and infrastructure.
Timing varies: some are immediate (Akero), some are medium‑term (Fractyl’s pivotal data; IREN’s rollout).
Because only ~62% of records were processed (~4,740/7,656), there may be other signals in the unprocessed data that could equal or exceed these.
Always supplementary research required: check latest filings, management commentary, and compare valuations.
For any investment decision, further due diligence and consideration of your risk tolerance and investment goals are recommended.
Make your next move count.
Stacy
Founder, CEO - Smart Movers Club
We track boring things that create predictable wealth.
P.S. Every member’s at a different stage. Book a quick call and I’ll help you figure out which path makes the most sense for you.
If you were forwarded this email and would like to keep getting Club Daily delivered to your inbox, please subscribe below.
Disclaimer: This publication is for general informational and educational purposes only. It is not tailored to your circumstances, is not a complete statement of the matters discussed, and should not be relied upon as investment, legal, tax, accounting, regulatory, or other professional advice. Speak with your own professional advisors about how any information may apply to you.
Smart Movers Club LLC makes no representation or warranty, express or implied, as to the accuracy, completeness, timeliness, or suitability of the information and disclaims liability for any errors or omissions.
Nothing herein is an offer to sell, a solicitation to buy, or a recommendation of any security, financial instrument, or product. This publication does not form the basis of any contract and does not create a fiduciary, advisory, or client relationship with Smart Movers Club LLC. References to third-party content are for illustration only and are not endorsements. Smart Movers Club LLC is not responsible for the availability, accuracy, or content of third-party materials.
Past performance is not indicative of future results. Forward-looking statements involve risks and uncertainties and may change without notice.